Targets › UNKNOWN
58 programs from 52 companies in 176 trials: 80 Phase 2, 35 Phase 4, 35 Phase 3, 26 Phase 1; Infectious disease, Oncology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: the race on UNKNOWN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanderbilt University Medical Center | [18F]MH.MZ Bacterial penicillin-binding protein inhibitor | HTR2A, UNKNOWN, BDKRB2, Ion channels | Phase 4 | Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension … | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Wroclaw Medical University | Ferinject (FCM) Intravenous ferric carboxymaltose for iron repletion | UNKNOWN | Phase 4 | Myocardial Infarction, Acute | Dec 2026 |
| University of Iowa | Metronidazole 0.75% Topical Gel Antibiotic/antimicrobial agent (topical) | UNKNOWN | Phase 4 | Healthy | Dec 2026 |
| University of Alberta | Ciprofloxacin Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor | UNKNOWN | Phase 4 | Idiopathic Overactive Bladder; Neurogenic Bladder | Mar 2027 |
| University of California, San Francisco | n-acetylcysteine (NAC) Mucolytic agent that breaks down disulfide bonds in mucoproteins | UNKNOWN | Phase 4 | Asthma | Apr 2027 |
| National University of Singapore | Ceftazidime Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 4 | Blood Stream Infections; Bloodstream Infection | Oct 2027 |
| Monash University | Cefazolin Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 4 | Surgical Site Infection | Dec 2027 |
| Hospital de Clinicas de Porto Alegre | Cefuroxime Axetil Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 4 | Pyelonephritis in Pregnancy | Dec 2027 |
| Assistance Publique - Hôpitaux de Paris | Amikacin Aminoglycoside antibiotic; inhibits bacterial protein synthesis by binding to 30S ribosoma | UNKNOWN | Phase 4 | Pyelonephritis Acute; Pneumonia, Bacterial | Jan 2028 |
| Assistance Publique - Hôpitaux de Paris | Cefixime Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 4 | Pyelonephritis Acute | Jan 2028 |
| Assistance Publique - Hôpitaux de Paris | Cotrimoxazole (sulfamethoxazole/trimethoprime) Fixed-dose combination of sulfonamide and dihydrofolate reductase inhibitor; inhibits bact | UNKNOWN | Phase 4 | Pyelonephritis Acute | Jan 2028 |
| Theis S. Itenov | N-Acetylcysteine Antioxidant and glutathione precursor | UNKNOWN | Phase 4 | Sepsis | Feb 2028 |
| Cairo University | Acetyl cysteine Mucolytic agent that reduces mucus viscosity | UNKNOWN | Phase 4 | Ventilation Acquired Pneumonia | Mar 2028 |
| University of Newcastle, Australia | Rifampin Bacterial DNA-directed RNA polymerase inhibitor | UNKNOWN | Phase 4 | Prosthetic Joint Infections of Hip | Dec 2029 |
| University Hospital, Tours | Cefazolin Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 4 | Hemodialysis Catheter Infection | – |
| St. Joseph's Hospital and Medical Center, Phoenix | Gentamicin Bacterial 70S ribosome inhibitor | UNKNOWN | Phase 4 | Catheter Infection | – |
| The Aurum Institute NPC | Rifapentine Bacterial DNA-directed RNA polymerase inhibitor | RIPA, INH, UNKNOWN | Phase 4 | HIV Seropositivity | – |
| Colgate Palmolive | Colgate SNaP Total 10/10, 1.5 Taurate Stannous fluoride toothpaste (0.454% SnF, 1100 ppm F) with taurate | UNKNOWN | Phase 3 | Plaque, Dental | Nov 2026 |
| Sun Yat-sen University | CCRT with cisplatin DNA cross-linking alkylating agent | UNKNOWN | Phase 3 | Nasopharyngeal Carcinoma; Squamous Cell Carcinoma of Head and Neck; SBRT; Laryngeal Cancer … | Dec 2026 |
| Mt. Sinai Medical Center, Miami | Edetate Disodium Chelation therapy for removal of environmentally acquired toxic metals | UNKNOWN | Phase 3 | Critical Limb Ischemia | Dec 2026 |
| Wake Forest University Health Sciences | Magnesium Sulfate 2 G Electrolyte supplementation; antiarrhythmic mechanism likely via effects on cardiac conduc | UNKNOWN | Phase 3 | Tachycardia Atrial; Migraine | Dec 2026 |
| Suleyman Demirel University | N-acetyl cysteine Antioxidant; may reduce contrast-induced nephropathy and periprocedural myocardial injury | UNKNOWN | Phase 3 | Coronary Artery Disease; Acute ST Segment Elevation Myocardial Infarction | Dec 2026 |
| Radboud University Medical Center | Optimised dose rifampicin (1800 mg) Inhibition of bacterial RNA polymerase | UNKNOWN | Phase 3 | Tuberculosis, Pulmonary | Dec 2026 |
| Gilead Sciences | Lenacapavir Structural capsid protein inhibitor | CA, CPSF6, GAG, PROT, UNKNOWN, CAPSID | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection … | Mar 2027 |
| Vaxcyte | VAX-31 (low dose) 31 valent pneumococcal conjugate vaccine | UNKNOWN | Phase 3 | Pneumococcal Disease; Pneumococcal Vaccines | Mar 2027 |
| Medicines Development for Global Health | MoxDA Antiparasitic combination: moxidectin + diethylcarbamazine + albendazole for lymphatic fil | UNKNOWN | Phase 3 | Lymphatic Filariasis | Jun 2027 |
| West China Hospital | Oxaliplatin Third-generation platinum-based chemotherapy agent; forms DNA adducts and crosslinks | UNKNOWN | Phase 3 | Rectal Cancer; Gastroesophageal Junction Adenocarcinoma | Dec 2027 |
| Shanghai Jiao Tong University School of Medicine | cyclophosphamide (reduced-dose PTCy) Alkylating agent; post-transplantation cyclophosphamide causes selective alloreactive T-ce | UNKNOWN | Phase 3 | Allogeneic Hematopoietic Cell Transplant | Dec 2027 |
| Centre Hospitalier Universitaire de Nice | Rifampin Bacterial DNA-directed RNA polymerase inhibitor | UNKNOWN | Phase 3 | Infections Joint Prosthetic | May 2028 |
| University Hospital, Tours | Rabbit Anti thymocyte globulin (rATG) Polyclonal lymphocyte-depleting antibody targeting T lymphocytes | UNKNOWN | Phase 3 | Renal Transplant Rejection | Dec 2030 |
| Huashan Hospital | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | UNKNOWN | Phase 3 | Tuberculosis | – |
| Pirogov Russian National Research Medical University | Micronized purified flavonoid fraction (MPFF) 1000 Venotonic agent with angioprotective properties; reduces venous distensibility and blood s | UNKNOWN | Phase 3 | Pelvic Venous Disorders | – |
| Medicines Development for Global Health | Moxidectin Antiparasitic agent targeting nematode neuromuscular function | UNKNOWN | Phase 3 | Onchocerciasis | – |
| The University of Texas Health Science Center at San Antonio | Lomustine Nitrosourea alkylating agent | UNKNOWN | Phase 2 | Glioblastoma | Nov 2026 |
| Fudan University | Vitamin C Antioxidant, potential pro-oxidant at high doses | UNKNOWN | Phase 2 | Pancreatic Cancer | Nov 2026 |
| Thomas Jefferson University | N acetyl cysteine (NAC) Antioxidant; precursor for glutathione synthesis; may support dopaminergic function | UNKNOWN | Phase 2 | Parkinson Disease | Jan 2027 |
| Michael Bau Mortensen | Oxaliplatin DNA cross-linking agent delivered via pressurized intraperitoneal aerosol chemotherapy (PI | UNKNOWN | Phase 2 | Peritoneum Cancer | Mar 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Stupp regimen (oral temozolomide) Oral alkylating agent | UNKNOWN | Phase 2 | Glioblastoma (GBM) | Apr 2027 |
| The University of Hong Kong | Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin Pressurized intraperitoneal aerosol delivery of oxaliplatin | UNKNOWN | Phase 2 | Peritoneal Metastases | Aug 2027 |
| Northern Jiangsu People's Hospital | Oxaliplatin Third-generation platinum-based alkylating agent | UNKNOWN | Phase 2 | Hepatocellular Carcinoma (HCC) | Sep 2027 |
| Tata Memorial Centre | Standardized Withaferin-A (SWA) Withaferin-A (standardized root extract of Withania somnifera) | UNKNOWN | Phase 2 | Hematological Malignancy | Jan 2028 |
| Vanderbilt University Medical Center | Metronidazole Nitroimidazole antibiotic targeting anaerobic bacteria and protozoa | UNKNOWN | Phase 2 | Acute Uncomplicated Diverticulitis | Apr 2028 |
| ECOG-ACRIN Cancer Research Group | Temozolomide Alkylating agent; methylates DNA to trigger apoptosis | UNKNOWN | Phase 2 | Gastric Neuroendocrine Carcinoma | Jan 2029 |
| Zhejiang Raygene Pharmaceuticals | tirapazamine Bioreductive hypoxic cytotoxin | UNKNOWN | Phase 2 | HCC | Apr 2029 |
| Memorial Sloan Kettering Cancer Center | Cord Blood Units (HPC(CB)) Allogeneic cord blood hematopoietic progenitor cell transplantation | UNKNOWN | Phase 2 | Acute Myelogenous Leukemia | Apr 2030 |
| Patrick Wagner, MD, FACS | Mitomycin C (HIPEC) Alkylating agent - DNA crosslinking | UNKNOWN | Phase 2 | Peritoneal (Metastatic) Cancer | Dec 2035 |
| Universiti Sains Malaysia | Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 Live Bifidobacterium species (probiotics) to maintain gut microbial balance | UNKNOWN | Phase 2 | Healthy Adults; Healthy Adult Volunteer | – |
| Hayder Adnan Fawzi | Metronidazole | UNKNOWN | Phase 2 | Cutaneous Leishmaniasis | – |
| University Hospital, Montpellier | Oxaliplatin Platinum-based alkylating agent; cross-links DNA | UNKNOWN | Phase 2 | Cholangiocarcinoma Non-resectable | – |
| National Cancer Institute (NCI) | Radium-223 Alpha particle-emitting radiotherapeutic for skeletal metastases | UNKNOWN | Phase 2 | Biochemical Recurrent Prostate Cancer | – |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3BNC117-LS HIV broadly neutralizing antibody | UNKNOWN | Phase 1 | HIV-1 | Mar 2027 |
| Roswell Park Cancer Institute | Melphalan Hydrochloride Alkylating agent; DNA crosslinking chemotherapy used in myeloablative conditioning | UNKNOWN | Phase 1 | Acute Myeloid Leukemia in Remission | May 2027 |
| University of Virginia | Rifampin Bacterial DNA-directed RNA polymerase inhibitor | UNKNOWN | Phase 1 | Tuberculosis | Dec 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Mitomycin C (MMC) Antineoplastic alkylating agent delivered intraperitoneally as aerosol | UNKNOWN | Phase 1 | Peritoneal Carcinomatosis | Mar 2028 |
| General Oncology | Melphalan Alkylating agent (nitrogen mustard derivative) | UNKNOWN | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Retinoblastoma; Primary Immunodeficiency (PID); Refractory and/or Relapsed Metastatic Solid Tumors … | Dec 2028 |
| The Aurum Institute NPC | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | UNKNOWN | Phase 1 | HIV Seropositivity | – |
| Iterum Therapeutics, International | Sulopenem Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 1 | Pharmacokinetics After Oral Intake | – |
HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) Pneumococcal Vaccines (5) HIV Seropositivity (4) Obstructive Sleep Apnea (4) HIV-1 Infection (3) Pyelonephritis Acute (3) Pancreatic Cancer (2) Peritoneal (Metastatic) Cancer (2) Multiple Myeloma (2) HIV Pre-exposure Prophylaxis (2) Peritoneal Metastases (2)
small molecule (46), mixed (3), protein or peptide (3), antibody (1)
Assistance Publique - Hôpitaux de Paris (3) University Hospital, Tours (2) The Aurum Institute NPC (2) Vanderbilt University Medical Center (2) Medicines Development for Global Health (2) Fudan University (1) Theis S. Itenov (1) Pirogov Russian National Research Medical University (1) Wroclaw Medical University (1) Roswell Park Cancer Institute (1) Universiti Sains Malaysia (1) University of Alberta (1) St. Joseph's Hospital and Medical Center, Phoenix (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Patrick Wagner, MD, FACS (1) General Oncology (1) Monash University (1) Gilead Sciences (1) The University of Hong Kong (1) Cairo University (1)
HTR2A (2) CA (1) CPSF6 (1) GAG (1) PROT (1) CAPSID (1) RIPA (1) INH (1) SLC5A2 (1) SLC6A2 (1) GLP1R (1) Tubulin (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.